Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Rheumatic Disease ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Extrahepatic manifestations of chronic hepatitis C virus infection.Dig Liver Dis. 2014; 46: S165-S173
- Hepatitis C virus syndrome: a constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin’s lymphoma, and cancer.World J Hepatol. 2015; 7: 327-343
- Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C.Arthritis Rheum. 1999; 42: 2204-2212
- Extrahepatic manifestations of chronic hepatitis C virus infection: 297 cases from a tertiary medical center in Beijing, China.Chin Med J (Engl). 2014; 127: 1206-1210
- Prevalence of rheumatologic manifestations of chronic hepatitis C virus infection among Egyptians.Clin Rheumatol. 2010; 29: 1373-1380
- Prevalence and risk factors for patient-reported joint pain among patients with HIV/hepatitis C coinfection, hepatitis C monoinfection, and HIV monoinfection.BMC Musculoskelet Disord. 2015; 16: 93
- Causes and predictive factors of mortality in a cohort of patients with hepatitis C virus-related cryoglobulinemic vasculitis treated with antiviral therapy.J Rheumatol. 2010; 37: 615-621
- Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients.Semin Arthritis Rheum. 2004; 33: 355-374
- Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis.Arthritis Rheum. 2011; 63: 1748-1757
- Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d’Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l’Hepatite C.Medicine (Baltimore). 2000; 79: 47-56
- Cryoglobulinaemia and rheumatic manifestations in patients with hepatitis C virus infection.Ann Rheum Dis. 1998; 57: 728-731
- Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study.Ann Rheum Dis. 2016; 75: 1777-1782
- Extra-hepatic manifestations of hepatitis C—a meta-analysis of prevalence, quality of life, and economic burden.Gastroenterology. 2016; 150: 1599-1608
- How hepatitis C virus modifies the immunological profile of Sjögren syndrome: analysis of 783 patients.Arthritis Res Ther. 2015; 17: 250
- Sjögren syndrome associated with hepatitis C virus: a multicenter analysis of 137 cases.Medicine (Baltimore). 2005; 84: 81-89
- In situ detection of hepatitis C virus RNA in salivary glands.Am J Pathol. 2001; 158: 259-264
- Sialadenitis histologically resembling Sjogren syndrome in mice transgenic for hepatitis C virus envelope genes.Proc Natl Acad Sci U S A. 1997; 94: 233-236
- Serum autoantibodies positivity prevalence in patients with chronic HCV and impact on pegylated interferon and ribavirin treatment response.Liver Int. 2013; 33: 1504-1509
- Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C.J Clin Pathol. 2008; 61: 333-337
- Extrahepatic manifestations and autoantibodies in patients with hepatitis C virus infection.Clin Dev Immunol. 2012; 2012: 871401
- Expansion of functionally anergic CD21-/low marginal zone-like B cell clones in hepatitis C virus infection-related autoimmunity.J Immunol. 2011; 187: 6550-6563
- Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis.N Engl J Med. 2011; 365: 2067-2077
- Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis.Genes Immun. 2014; 15: 500-505
- Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fcγ receptors.Arthritis Rheum. 2011; 63: 1446-1451
- Study of the infection of human blood derived monocyte/macrophages with hepatitis C virus in vitro.J Med Virol. 2001; 65: 14-22
- Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme.Cell. 2000; 102: 553-563
- Chronic hepatitis C virus infection, a new cardiovascular risk factor?.Liver Int. 2016; 36: 621-627
- Myocardial injury in patients with chronic hepatitis C infection.J Hepatol. 2013; 58: 11-15
- Interferon-based treatment of hepatitis C virus infection reduces all-cause mortality in patients with end-stage renal disease: an 8-year nationwide cohort study in Taiwan.Medicine (Baltimore). 2015; 94: e2113
- Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients.Hepatology. 2014; 59: 1293-1302
- Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan.Aliment Pharmacol Ther. 2013; 38: 415-423
- Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C.Hepatology. 2014; 60: 823-831
- Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new-onset diabetes: A nationwide cohort study.Hepatology. 2014; 60: 807-814
- Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy.Int J Cancer. 2011; 128: 2344-2352
- Meta-analysis: insulin resistance and sustained virological response in hepatitis C.Aliment Pharmacol Ther. 2011; 34: 297-305
- Disease characteristics and treatment patterns in veterans with rheumatoid arthritis and concomitant hepatitis C infection.Arthritis Care Res. 2015; 67: 467-474
- Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study.J Hepatol. 2005; 42: 632-638
- Antiviral therapy for hepatitis C virus–associated mixed cryoglobulinemia vasculitis: a long-term followup study.Arthritis Rheum. 2006; 54: 3696-3706
- Cryoglobulinemia vasculitis.Am J Med. 2015; 128: 950-955
- Development of anti-CCP-positive rheumatoid arthritis following pegylated interferon-α2a treatment for chronic hepatitis C infection.J Rheumatol. 2010; 37: 1777
- Rheumatoid arthritis following PEG-interferon-alfa-2a plus ribavirin treatment for chronic hepatitis C: a case report and review of the literature.BMC Res Notes. 2013; 6: 437
- Systemic lupus erythematosus and Sjögren’s syndrome induced in a case by interferon-alpha used for the treatment of hepatitis C.Lupus. 2010; 19: 753-755
- Interferon alpha and neuromuscular disorders.J Neuroimmunol. 2009; 207: 3-17
- Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: A prospective, controlled pilot study.Dig Liver Dis. 2014; 46: 833-837
- PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis.J Hepatol. 2015; 62: 24-30
- Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.N Engl J Med. 2014; 370: 1889-1898
- Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.N Engl J Med. 2014; 370: 211-221
- Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection.Gastroenterology. 2016; 150: 419-429
- Daclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life.Hepat Med. 2016; 8: 21-26
- Treatment of hepatitis C virus–associated mixed cryoglobulinemia with direct-acting antiviral agents.Hepatology. 2016; 63: 408-417
- HCV-related mixed cryoglobulinemia: data from PITER, a nationwide Italian HCV cohort study.J Hepatol. 2016; 64: S618
- A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis.Arthritis Rheum. 2012; 64: 843-853
- A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis.Arthritis Rheum. 2012; 64: 835-842
- Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia.Blood. 2010; 116 ([quiz: 504–5]): 326-334
- Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study.Blood. 2010; 116: 343-353
- Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis.Arthritis Rheum. 2009; 60: 3848-3855
- Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study.Blood. 1994; 84: 3336-3343
- Plasma exchange and interferon-alpha pharmacokinetics in patients with hepatitis C virus-associated systemic vasculitis.Nephron. 2002; 91: 627-630
- Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, -2, and -3 clinical trials.Hepatology. 2015; 61: 1798-1808
- Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition.J Hepatol. 2012; 56: 549-556
Article info
Publication history
Published online: October 22, 2016
Footnotes
Conflict of Interest: P. Cacoub has received consultancies, honoraria, advisory board, or speakers’ fees from Abbvie, AstraZeneca, Bayer, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Janssen, Merck Sharp and Dohme, Pfizer, Roche, Servier, and Vifor. A.C. Desbois has received speakers’ fees from Gilead. C. Commarmond has no conflicts of interest. D. Saadoun has received speakers’ fees from Gilead.
Financial support: None.
Identification
Copyright
© 2016 Elsevier Inc. All rights reserved.
